[HTML][HTML] Rituximab in B-cell hematologic malignancies: a review of 20 years of clinical experience
G Salles, M Barrett, R Foà, J Maurer, S O'Brien… - Advances in …, 2017 - Springer
Rituximab is a human/murine, chimeric anti-CD20 monoclonal antibody with established
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
efficacy, and a favorable and well-defined safety profile in patients with various CD20 …
Rituximab: mechanism of action and resistance
DG Maloney, B Smith, A Rose - Seminars in oncology, 2002 - Elsevier
Rituximab (Rituxan; Genentech, Inc, South San Francisco, CA, and IDEC Pharmaceuticals,
San Diego, CA)-mediated killing of CD20-positive tumor cells is likely caused by a …
San Diego, CA)-mediated killing of CD20-positive tumor cells is likely caused by a …
Anti-CD20 antibody therapy for B-cell lymphomas
DG Maloney - New England Journal of Medicine, 2012 - Mass Medical Soc
A 62-year-old man receives a diagnosis of diffuse large B-cell lymphoma; treatment with a
regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been …
regimen including the anti-CD20 antibody rituximab is recommended. Rituximab has been …
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma
DG Maloney, AJ Grillo-López, CA White… - Blood, The Journal …, 1997 - ashpublications.org
Abstract IDEC-C2B8 is a chimeric monoclonal antibody (MoAb) directed against the B-cell–
specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates …
specific antigen CD20 expressed on non-Hodgkin's lymphomas (NHL). The MoAb mediates …
Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study
Background Lisocabtagene maraleucel (liso-cel) is an autologous, CD19-directed, chimeric
antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel …
antigen receptor (CAR) T-cell product. We aimed to assess the activity and safety of liso-cel …
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
PA McSweeney, D Niederwieser… - Blood, The Journal …, 2001 - ashpublications.org
Toxicities have limited the use of allogeneic hematopoietic cell transplantation (HCT) to
younger, medically fit patients. In a canine HCT model, a combination of postgrafting …
younger, medically fit patients. In a canine HCT model, a combination of postgrafting …
Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT
We previously reported that the Charlson Comorbidity Index (CCI) was useful for predicting
outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT) …
outcomes in patients undergoing allogeneic hematopoietic cell transplantation (HCT) …
[HTML][HTML] CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
BACKGROUND. T cells that have been modified to express a CD19-specific chimeric
antigen receptor (CAR) have antitumor activity in B cell malignancies; however, identification …
antigen receptor (CAR) have antitumor activity in B cell malignancies; however, identification …
Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells
Lymphodepletion chemotherapy followed by infusion of CD19-targeted chimeric antigen
receptor–modified T (CAR-T) cells can be complicated by neurologic adverse events (AE) in …
receptor–modified T (CAR-T) cells can be complicated by neurologic adverse events (AE) in …
Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial
CA Jacobson, JC Chavez, AR Sehgal… - The lancet …, 2022 - thelancet.com
Background Most patients with advanced-stage indolent non-Hodgkin lymphoma have
multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric …
multiple relapses. We assessed axicabtagene ciloleucel autologous anti-CD19 chimeric …